Display Settings:

Format

Send to:

Choose Destination

    Diabetes. 2005 Nov;54(11):3245-51.

    Homocysteine metabolism in ZDF (type 2) diabetic rats.

    Wijekoon EP, Hall B, Ratnam S, Brosnan ME, Zeisel SH, Brosnan JT.

    Department of Biochemistry, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

    Mild hyperhomocysteinemia is a risk factor for many diseases, including cardiovascular disease. We determined the effects of insulin resistance and of type 2 diabetes on homocysteine (Hcy) metabolism using Zucker diabetic fatty rats (ZDF/Gmi fa/fa and ZDF/Gmi fa/?). Plasma total Hcy was reduced in ZDF fa/fa rats by 24% in the pre-diabetic insulin-resistant stage, while in the frank diabetic stage there was a 59% reduction. Hepatic activities of several enzymes that play a role in the removal of Hcy:cystathionine beta-synthase (CBS), cystathionine gamma-lyase, and betaine:Hcy methyltransferase (BHMT) were increased as was methionine adenosyltransferase. CBS and BHMT mRNA levels and the hepatic level of S-adenosylmethionine were also increased in the ZDF fa/fa rats. Studies with primary hepatocytes showed that Hcy export and the transsulfuration flux in cells from ZDF fa/fa rats were particularly sensitive to betaine. Interestingly, liver betaine concentration was found to be significantly lower in the ZDf fa/fa rats at both 5 and 11 weeks. These results emphasize the importance of betaine metabolism in determining plasma Hcy levels in type 2 diabetes.

    PMID: 16249451 [PubMed - indexed for MEDLINE]

    PMCID: 2435380

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Betaine (Cystadane®)

      Betaine is used to treat homocystinuria (an inherited condition in which the body cannot break down a certain protein, causing build-up of homocysteine in the blood). Increased amounts of homocysteine in the body can cau...